Skip to content
ATLAS PREP HQ
Healing

KLOW

Blend of GHK-Cu + BPC-157 + TB-500 + KPV

Regenerative blend combining GHK-Cu, BPC-157, TB-500, and KPV for tissue-repair and inflammation research.

Preclinical Evidence

Route

Subcutaneous research blend.

Common format

GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg

Research focus

tissue repair

Evidence level

Preclinical Evidence

Typical cycle

8–16 weeks

Healing research motifHealing

KLOW in 30 seconds

Atlas Fast Read

What it is

Blend of GHK-Cu + BPC-157 + TB-500 + KPV

Why people care

Regenerative blend combining GHK-Cu, BPC-157, TB-500, and KPV for tissue-repair and inflammation research.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

The fixed four-compound blend lacks controlled human efficacy data and has unresolved formulation chemistry. pH incompatibility, copper displacement, peptide degradation, aggregation, dose accuracy and post-mix stability are central unanswered questions.

Bottom line

KLOW is scientifically interesting for tissue repair, inflammation, but the current case is driven mainly by cell and animal data.

Overview

What is KLOW?

KLOW is a multi-compound research blend rather than a single peptide. It combines several repair- and inflammation-oriented peptides in one formulation, so any claim about the blend must be separated from evidence on its individual ingredients.

KLOW is a recent research/compounding blend combining GHK-Cu, BPC-157, TB-500, and KPV. It has no independent clinical-development history as a four-drug product.

Mechanism

How it works

Combines the proposed repair actions of GHK-Cu, BPC-157 and TB-500 with KPV's anti-inflammatory signaling. The four-way mixture has no direct clinical efficacy evidence and compatibility/stability may differ from each component alone.

Research areas

tissue repairinflammationskin remodelinggastrointestinal repair research

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

There are no controlled human trials of the four-compound KLOW blend. Human claims are indirect, based on ingredients with very different evidence levels and routes of study.

Preclinical evidence

No direct preclinical program validates the fixed four-way blend. Its rationale is assembled from separate work on GHK-Cu, BPC-157, TB-500/thymosin-beta-4, and KPV.

Knowledge gaps

The fixed four-compound blend lacks controlled human efficacy data and has unresolved formulation chemistry. pH incompatibility, copper displacement, peptide degradation, aggregation, dose accuracy and post-mix stability are central unanswered questions.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources blend titration provides approximately 250→750 mcg each of TB-500, BPC-157 and KPV plus 1.25→3.75 mg GHK-Cu per day, with lower maintenance later.

Frequency

Once daily.

Timing

No validated timing advantage.

Route

Subcutaneous research blend.

Cycle length

8–16 weeks

Reconstitution

Community sources list 3 mL bacteriostatic water per 80 mg blend. community sources argues the fixed blend has incompatible pH/stability requirements across GHK-Cu, BPC-157, TB-500 and KPV. Atlas should flag mixture stability as unresolved rather than present the reconstitution as validated.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C and use within 4 weeks.

Monitoring

No validated monitoring standard. Track target tissue/GI/skin outcomes, CBC/CMP and injection reactions; copper/zinc can be considered if systemic GHK-Cu exposure is prolonged.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.

Contraindications

No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.

Interactions

Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.

Stacks

Common stacks

KLOW blend

This entry is already GHK-Cu + BPC-157 + TB-500 + KPV.

No controlled human evidence on the fixed blend; mixture stability and compatibility remain concerns.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

KLOW is scientifically interesting for tissue repair, inflammation, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Healing

Healing

Ara-290

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Read guide

Healing

BPC-157

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Read guide

Healing

BPC-157 + TB-500

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Read guide